1531-8249/asset/olbannerleft.gif?v=1&s=d36d5ebb3caa1b29d7f078a97c52973b0963daf2)
1531-8249/asset/olbannerright.gif?v=1&s=078041b213f6959d63575a593f880457c45116f0)
Original Article
You have free access to this content
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis
Article first published online: 20 JAN 2010
DOI: 10.1002/ana.21972
Copyright © 2010 American Neurological Association
1531-8249/asset/cover.gif?v=1&s=685ec69724c5ed4c8847ce939e70ceb45065856f "Annals of Neurology")
Additional Information
How to Cite
Mowry, E. M., Krupp, L. B., Milazzo, M., Chabas, D., Strober, J. B., Belman, A. L., McDonald, J. C., Oksenberg, J. R., Bacchetti, P. and Waubant, E. (2010), Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol., 67: 618–624. doi: 10.1002/ana.21972
Publication History
- Issue published online: 26 APR 2010
- Article first published online: 20 JAN 2010
- Manuscript Accepted: 5 JAN 2010
- Manuscript Revised: 15 DEC 2009
- Manuscript Received: 3 NOV 2009
Funded by
- National Multiple Sclerosis Society Sylvia Lawry Fellowship Award
- National MS Society. Grant Number: A103210
- Donation from a patient's family
REFERENCES
- 1, , , , . Vitamin D levels and disease state in Texas patients with systemic lupus erythematosus. Am J Med Sci 2008; 335: 99–104.
- 2, , , et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500–1503.
- 3, , , et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.
- 4, . Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005; 175: 4119–4126.
- 5, , , et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009; 5: e1000369.
- 6, , , et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004; 74: 160–167.
- 7, , , for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68( suppl 2): S7–S12.
- 8, , , et al. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol 2009; 256: 1061–1066.
- 9, , . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290–297Direct Link:
- 10, , , . A pilot study of MRI activity before and during interferon beta-1a therapy. Neurology 1999; 53: 874–876.
- 11, , , et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006; 15: 2813–2824.
- 12, , , et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Gen 2003; 72: 710–716.
- 13, , , et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009; 132: 250–259.
- 14. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353–373.
- 15, , , et al. Extra-renal 25-hydroxyvitamin D in human health and disease. J Steroid Biochem Mol Biol 2007; 103: 316–321.
- 16, . Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67: 1232–1236.
- 17, , , , . Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14: 1220–1224.
- 18, , , et al. The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ Health Perspect 2007; 115: 1132–1139.
- 19, , , et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008; 31: 271–279.
- 20, , . Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986; 21: 193–200.
- 21, , , et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 1294–1296.
- 22, , , . Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86: 645–651.
- 23, , , et al. TGFβ- and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J Immunol 2005; 174: 2061–2070.
- 24, , , et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770–1773.
- 25, , , et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179: 1634–1647.
- 26, , , et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006; 177: 8504–8511.
- 27, , , , . A 1α,25-dihydroxyvitamin D3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367–1374.
- 28, , . Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009; 132: 1146–1160.
- 29, , , . Seasonal variations in serum levels of 25-hydroxyvitamin D and parathyroid hormone but no detectable change in femoral neck bone density in an older population with regular outdoor exposure. J Am Geriatr Soc 2001; 49: 1190–1196.Direct Link:
- 30, , , et al. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metabolism 1999; 48: 1028–1032.
- 31, . Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008; 122: 1142–1152.
- 32, , , et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204–210.